Parents are increasingly exploring weight-loss medications like Wegovy for their children, driven by the ineffectiveness of traditional diet and exercise methods for some. This trend follows the FDA's approval of Wegovy for adolescents aged 12 and older in late 2022. For example, Demi Buckley, a teenager from Saginaw, Michigan, lost 58 pounds after starting Wegovy in March 2023, after previous attempts at weight loss were unsuccessful. Her mother, Deana, who had personal experience with weight struggles and bariatric surgery, was supportive of Demi trying the medication. While popular, Wegovy is not approved for elementary school-aged children, and the American Academy of Pediatrics updated its guidelines to include anti-obesity medications for children aged 12 and up only after behavioral and lifestyle changes prove insufficient.
The rise in adolescent Wegovy prescriptions is notable, with health data firm Truveta reporting a 50% increase in the average rate of teenagers starting treatment in 2024, reaching 14.8 prescriptions per 100,000 adolescents, up from 9.9 per 100,000 in 2023. Despite this increase, it represents a small fraction of the estimated 8 million American teens living with obesity. Novo Nordisk, Wegovy's manufacturer, stated that studies did not indicate the medicine affected growth, emphasizing that prescription decisions are at a physician's discretion.
However, significant concerns remain regarding the long-term safety and effectiveness of these drugs in children. The U.S. Preventive Services Task Force recommends prioritizing lifestyle changes for adolescents until more data on long-term drug safety is available. Some doctors worry that reliance on medication alone could lead to nutritional deficiencies or eating disorders. Medical experts also point out the challenges in providing alternative, intensive behavioral counseling, which is recommended but often unavailable, not covered by insurance, or difficult for families to commit to. For instance, less than 1% of the nearly 15 million U.S. children with obesity receive this type of structured care, according to the CDC.
Financial barriers are also a significant hurdle. Wegovy can cost around $1,300 per month, and insurance coverage is frequently an issue. A full year of intensive behavioral counseling, like the program at Stanford, can cost $3,500, often paid out-of-pocket, despite being recommended by leading medical groups. The CDC has stated that equitable access to both medication and lifestyle treatments is crucial. This situation places families in a difficult position, weighing the potential benefits of new medications against concerns about long-term effects, cost, and the scarcity of comprehensive alternative treatments.
The growing use of Wegovy among adolescents is a "monumental shift" in childhood obesity treatment, driven by the profound physical and emotional burden of obesity on teens, including social stigma and health issues. Pediatricians previously had limited effective options beyond diet and exercise. Randy, a parent, expressed his hope that Wegovy remains available for children, sharing that his daughter, Katie, is not scared of the medication. This shift highlights a complex landscape where medical advancements offer new hope, but also introduce new questions and challenges for parents, doctors, and the healthcare system.
